title: Post-coupling strategy enables true receptor-targeted nanoparticles.
abstract: A key goal of our research is the targeted delivery of functional biopharmaceutical agents of interest, such as small interfering RNA (siRNA), to selected cells by means of receptor-mediated nanoparticle technologies. Recently, we described how pH-triggered, PEGylated siRNA-nanoparticles (pH triggered siRNA-ABC nanoparticles) were able to mediate the passive targeting of siRNA to liver cells in vivo. In addition, PEGylated siRNA nanoparticles enabled for long-term circulation (LTC siRNA-ABC nanoparticles, LEsiRNA nanoparticles) were shown to do the same to tumour cells in vivo. Further gains in the efficiency of siRNA delivery are expected to require active targeting with nanoparticles targeted for delivery and cellular uptake by means of attached biological ligands. Here we report on the development of a new synthetic chemistry and a bioconjugation methodology that allows for the controlled formulation of PEGylated nanoparticles which surface-present integrin-targeting peptides unambiguously and so enable integrin receptor-mediated cellular uptake. Furthermore, we present delivery data that provide a clear preliminary demonstration of physical principles that we propose should underpin successful, bonefide receptor-mediated targeted delivery of therapeutic and/or imaging agents to cells.
authors.affiliation: Imperial College Genetic Therapies Centre, Department of Chemistry, Flowers Building, Armstrong Road, Imperial College London, London SW7 2AZ, UK.
authors.forename: Jianmeizi
authors.initials: J
authors.lastname: Chen
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jorgensen
authors.forename: Maya
authors.initials: M
authors.lastname: Thanou
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Miller
references.citation: Cancer Res. 2007 Aug 15;67(16):7833-40
references.pmid: 17699789
references.citation: Bioconjug Chem. 2009 Apr;20(4):648-55
references.pmid: 19368341
references.citation: Chembiochem. 2005 Jul;6(7):1212-23
references.pmid: 15937988
references.citation: Tumori. 2008 Mar-Apr;94(2):234-45
references.pmid: 18564612
references.citation: Org Biomol Chem. 2010 Jan 7;8(1):201-11
references.pmid: 20024151
references.citation: Nucl Med Biol. 2004 Jan;31(1):11-9
references.pmid: 14741566
references.citation: Mol Pharm. 2009 May-Jun;6(3):706-17
references.pmid: 19159285
references.citation: Bioconjug Chem. 2009 Jan;20(1):32-40
references.pmid: 19099499
references.citation: J Virol. 2008 Feb;82(3):1537-46
references.pmid: 18045932
references.citation: J Biol Chem. 2007 Mar 30;282(13):9657-9665
references.pmid: 17244604
references.citation: Chembiochem. 2008 Jan 25;9(2):219-31
references.pmid: 18076008
references.citation: Biochemistry. 2003 May 27;42(20):6067-77
references.pmid: 12755608
references.citation: J Control Release. 2010 Apr 19;143(2):222-32
references.pmid: 19969034
references.citation: Cancer Res. 2009 Jul 15;69(14):5843-50
references.pmid: 19549907
references.citation: Angew Chem Int Ed Engl. 1999 Jul 12;38(13-14):1949-1952
references.pmid: 34182669
references.citation: J Control Release. 2011 Jan 20;149(2):111-6
references.pmid: 20888381
references.citation: Chem Soc Rev. 2005 Nov;34(11):970-94
references.pmid: 16239997
references.citation: Hum Gene Ther. 1998 May 1;9(7):1037-47
references.pmid: 9607415